Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | EP0042 |
| Synonyms | |
| Therapy Description |
EP0042 inhibits FLT3 and Aurora kinase, potentially leading to impaired chromosome segregation and decreased proliferation of FLT3- or Aurora kinase-overexpressing tumor cells (NCI Drug Dictionary). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| EP0042 | EP 0042|EP-0042 | AURK Inhibitor (Pan) 12 FLT3 Inhibitor 69 | EP0042 inhibits FLT3 and Aurora kinase, potentially leading to impaired chromosome segregation and decreased proliferation of FLT3- or Aurora kinase-overexpressing tumor cells (NCI Drug Dictionary). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT04581512 | Phase Ib/II | EP0042 Azacitidine + EP0042 + Venetoclax | Study to Evaluate the Safety and Tolerability of EP0042 | Recruiting | NLD | GBR | AUS | 0 |